权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chromatin maintenance in cancer progression

癌症进展中的染色质维持

基本信息

批准号：
9150499
负责人：
Ian J Davis
金额：
$ 45.97万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-30 至 2020-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9150499
关键词：
Biochemical Biochemical Genetics Biological Markers Biological Models C-terminal Cancer Cell Growth Regulation Cells Childhood Acute Lymphocytic Leukemia Chromatin Clear Cell DNA Damage DNA Methylation DNA Modification Methylases DNA Repair DNMT3a Data Defect Development Disease Disease Progression Dissection Double Strand Break Repair Environment Event Frequencies Future Genes Genetic Transcription Genome Genomic Instability Genomic approach Genomics Growth Histone H3 Histones Human Individual Kidney Neoplasms Link Lysine Maintenance Malignant Neoplasms Malignant neoplasm of urinary bladder Mediating Mediator of activation protein Messenger RNA Modeling Mutate Mutation Neoplasm Metastasis Nucleosomes Orthologous Gene Pathway interactions Pattern Phenotype Positioning Attribute Process Property Proteins RNA Polymerase II RNA Processing RNA Splicing Reader Refractory Regulation Regulator Genes Renal Cell Carcinoma Renal carcinoma Reporting Research Personnel Role SET Domain Severities Signal Transduction Structure-Activity Relationship Testing Therapeutic Therapeutic Intervention Transcript Transcription Process Transcriptional Regulation Tumor Cell Biology Tumor Suppression Yeasts base cancer cell comparative genomics functional genomics genetic approach genetic regulatory protein high risk histone methylation histone methyltransferase histone modification homologous recombination kidney cell loss of function metaplastic cell transformation mutant neoplastic cell novel nuclease programs public health relevance repaired response tumor tumor progression tumorigenesis

项目摘要

DESCRIPTION (provided by applicant): Mutations in chromatin regulatory proteins have recently been identified in a wide range of human cancers. Although these mutations are associated with disease progression, how they contribute to tumorigenesis remains unknown. We propose to investigate SETD2, a non-redundant histone methyltransferase that preferentially places a trimethylation mark on Histone H3 on lysine 36 in actively transcribed gene bodies. This gene is mutated in approximately 15% of renal cell carcinomas, and is being identified in a growing list of tumors. By examining chromatin organization in primary human tumors, we observed that SETD2 mutation and loss of its histone modification were associated with changes in nucleosome accessibility and widespread alteration in RNA processing. We hypothesize that histone mark dysregulation through SETD2 loss is an important component of tumorigenesis. We propose a highly collaborative project that employs biochemical, genetic and genomic approaches to comprehensively explore the effect of SETD2 mutation on chromatin and transcription, in an effort to unravel the mechanisms by which SETD2 loss leads to the promotion of cancer. To this end, we have generated a unique set of cell-based model systems which uses comparative genomic studies between human and yeast cells. We have additionally established novel domain-specific activities of SETD2, and the first demonstration of functional mutations separating di-methylating from tri-methylating activity. We propose three complementary aims: 1) to define the chromatin reprogramming and transcriptional effects of SETD2 mutation, revealing critical mechanistic features that link histone modification and nucleosome position to the transcriptional and DNA repair defects associated with SETD2 loss, 2) to utilize the separation of function revealed by high severity SETD2 mutants in the catalytic (SET) domain and the RNA polymerase II interactions domain (SRI) to reveal important determinants of the genomic phenotype, and 3) to explore discrete functions associated with SETD2 loss mediated by the altered H3K36me3 mark, by systematically examining the histone "reader" molecules that transduce signals for DNA methylation, DNA repair, and transcriptional elongation. Taken together, these studies will define the mechanistic link between SETD2 loss of function and cancer development, as well as reveal novel opportunities for biomarker or therapeutic interventions.